Literature DB >> 28120141

Autoimmune Movement Disorders: a Clinical and Laboratory Approach.

Josephe Archie Honorat1, Andrew McKeon2,3,4.   

Abstract

Autoimmune movement disorders are caused by an aberrant immune response to neural self-antigens. These disorders may be paraneoplastic, parainfectious, or (most commonly) idiopathic. The neurological presentations are diverse, and sometimes multifocal. Movement disorders can occur as part of the spectrum with phenotypes including chorea, myoclonus, ataxia, CNS hyperexcitability (including stiff-person syndrome), dystonia, and parkinsonism. Symptoms are subacute in onset and may have a fluctuating course. The best characterized disorders are unified by neural autoantibodies identified in serum or cerebrospinal fluid. The antibody specificity may predict the association with cancer and the response to immunotherapy. In this article, we review autoimmune-mediated movement disorders, associated cancers, diagnosis, and treatment.

Entities:  

Keywords:  Autoimmunity; Immunotherapy; Movement disorders; Neuronal autoantibodies; Paraneoplastic

Mesh:

Substances:

Year:  2017        PMID: 28120141     DOI: 10.1007/s11910-017-0709-2

Source DB:  PubMed          Journal:  Curr Neurol Neurosci Rep        ISSN: 1528-4042            Impact factor:   5.081


  102 in total

1.  Immunomodulated parkinsonism as a presenting symptom of LGI1 antibody encephalitis.

Authors:  Monica M Kurtis; Rafael Toledano; Irene García-Morales; Antonio Gil-Nagel
Journal:  Parkinsonism Relat Disord       Date:  2015-08-18       Impact factor: 4.891

2.  Human neurexin-3α antibodies associate with encephalitis and alter synapse development.

Authors:  Nuria Gresa-Arribas; Jesús Planagumà; Mar Petit-Pedrol; Izumi Kawachi; Shinichi Katada; Carol A Glaser; Mateus M Simabukuro; Thaís Armangué; Eugenia Martínez-Hernández; Francesc Graus; Josep Dalmau
Journal:  Neurology       Date:  2016-05-11       Impact factor: 9.910

3.  Paraneoplastic Neurological Syndromes and Glutamic Acid Decarboxylase Antibodies.

Authors:  Helena Ariño; Romana Höftberger; Nuria Gresa-Arribas; Eugenia Martínez-Hernández; Thaís Armangue; Michael C Kruer; Javier Arpa; Julio Domingo; Bojan Rojc; Luis Bataller; Albert Saiz; Josep Dalmau; Francesc Graus
Journal:  JAMA Neurol       Date:  2015-08       Impact factor: 18.302

4.  Mycoplasma pneumoniae associated opsoclonus-myoclonus syndrome in three cases.

Authors:  Benedikt Maria Huber; Susi Strozzi; Maja Steinlin; Christoph Aebi; Simon Fluri
Journal:  Eur J Pediatr       Date:  2009-09-24       Impact factor: 3.183

5.  Antibodies to surface dopamine-2 receptor in autoimmune movement and psychiatric disorders.

Authors:  Russell C Dale; Vera Merheb; Sekhar Pillai; Dongwei Wang; Laurence Cantrill; Tanya K Murphy; Hilla Ben-Pazi; Sophia Varadkar; Tim D Aumann; Malcolm K Horne; Andrew J Church; Thomas Fath; Fabienne Brilot
Journal:  Brain       Date:  2012-10-11       Impact factor: 13.501

6.  GAD antibody positive paraneoplastic stiff person syndrome in a patient with renal cell carcinoma.

Authors:  John C McHugh; Brian Murray; Radhakrishnan Renganathan; Sean Connolly; Tim Lynch
Journal:  Mov Disord       Date:  2007-07-15       Impact factor: 10.338

7.  Stiff person syndrome improvement with chemotherapy in a patient with cutaneous T cell lymphoma.

Authors:  Goran Rakocevic; Aamir Hussain
Journal:  Muscle Nerve       Date:  2013-04-21       Impact factor: 3.217

Review 8.  Autoimmune movement disorders.

Authors:  Andrew Mckeon; Angela Vincent
Journal:  Handb Clin Neurol       Date:  2016

9.  Clinical analysis of anti-Ma2-associated encephalitis.

Authors:  Josep Dalmau; Francesc Graus; Alberto Villarejo; Jerome B Posner; Deborah Blumenthal; Brian Thiessen; Albert Saiz; Patricio Meneses; Myrna R Rosenfeld
Journal:  Brain       Date:  2004-06-23       Impact factor: 13.501

10.  Clinical and Immunologic Investigations in Patients With Stiff-Person Spectrum Disorder.

Authors:  Eugenia Martinez-Hernandez; Helena Ariño; Andrew McKeon; Takahiro Iizuka; Maarten J Titulaer; Mateus M Simabukuro; Eric Lancaster; Mar Petit-Pedrol; Jesús Planagumà; Yolanda Blanco; Robert J Harvey; Albert Saiz; Francesc Graus; Josep Dalmau
Journal:  JAMA Neurol       Date:  2016-06-01       Impact factor: 18.302

View more
  4 in total

Review 1.  Shedding light on thyroid hormone disorders and Parkinson disease pathology: mechanisms and risk factors.

Authors:  S Mohammadi; M Dolatshahi; F Rahmani
Journal:  J Endocrinol Invest       Date:  2020-06-04       Impact factor: 4.256

2.  Myoclonus and hypercalcemia in a dog with poorly differentiated lymphoproliferative neoplasia.

Authors:  Cassia H Z Hare; Joy Archer; Emilie Cloup; Marie-Aude Genain; Katherine Hughes; Katie E McCallum; Lisa Alves
Journal:  J Vet Intern Med       Date:  2018-12-18       Impact factor: 3.333

3.  Phosphodiesterase 10A IgG: A novel biomarker of paraneoplastic neurologic autoimmunity.

Authors:  Anastasia Zekeridou; Thomas Kryzer; Yong Guo; Anhar Hassan; Vanda Lennon; Claudia F Lucchinetti; Sean Pittock; Andrew McKeon
Journal:  Neurology       Date:  2019-07-17       Impact factor: 9.910

Review 4.  Autoimmune and Paraneoplastic Chorea: A Review of the Literature.

Authors:  Kevin Kyle; Yvette Bordelon; Nagagopal Venna; Jenny Linnoila
Journal:  Front Neurol       Date:  2022-03-18       Impact factor: 4.003

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.